Biopharmaceutical company AstraZeneca (NASDAQ: AZN) on Wednesday announced a USD445m expansion of its manufacturing facility in Coppell, Texas, doubling production capacity for Lokelma to meet growing global demand.

The Coppell site, which supplies Lokelma to more than 50 countries, employs over 250 people. The expansion adds a 9,000-square-foot building with two new manufacturing lines, enhanced laboratory testing, warehousing and utility infrastructure, and additional administrative space.

The investment forms part of AstraZeneca's broader USD50bn plan to strengthen US research, development and manufacturing capabilities over the next five years, following the recent groundbreaking at its Albemarle County, Virginia facility.

At the unveiling event, AstraZeneca's STEM education partner Learning Undefeated showcased its mobile lab Breakout Box: Manufacturing Mission, aimed at inspiring students in Texas to pursue careers in advanced manufacturing and technology.

The US remains AstraZeneca's largest market, with 19 R&D, manufacturing, and commercial sites employing more than 25,000 people and supporting over 100,000 jobs nationwide. In 2025, the company contributed an estimated US20bn to the American economy.